Cerus Corporation (CERS) Bundle
Understanding Cerus Corporation (CERS) Revenue Streams
Understanding Cerus Corporation’s Revenue Streams
The revenue streams for the corporation primarily consist of product sales and government contracts. The core product is the INTERCEPT Blood System, which generates significant revenue through the sale of disposable kits.
Breakdown of Primary Revenue Sources
| Revenue Source | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Product Revenue | $46,017 | $39,772 | $6,245 | 16% |
| Government Contract Revenue | $4,639 | $7,479 | $(2,840) | (38%) |
| Total Revenue | $50,656 | $47,251 | $3,405 | 7% |
In the nine months ended September 30, 2024, product revenue was $129,461 thousand, compared to $109,599 thousand in the same period of 2023, reflecting an increase of $19,862 thousand or 18%. Conversely, government contract revenue decreased from $23,856 thousand in 2023 to $15,109 thousand in 2024, a decline of $8,747 thousand or (37%).
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate demonstrates a positive trend in product sales, while government contract revenue has experienced a decline due to the completion of specific projects. The overall revenue growth for the nine months ended September 30, 2024, was 8% compared to the same period in 2023.
Contribution of Different Business Segments to Overall Revenue
For the three months ended September 30, 2024, the contribution to total revenue from product sales was approximately 91%, while government contracts accounted for about 9%. This distribution reflects a significant reliance on product sales, particularly in North America.
Analysis of Significant Changes in Revenue Streams
The increase in product revenue is primarily attributed to growth in disposable platelet kit sales to U.S. customers, which underlines the rising market acceptance of the INTERCEPT Blood System. In contrast, the decrease in government contract revenue is linked to the completion of the ReCePI study funded by BARDA, resulting in reduced revenues from this source for the current fiscal year.
Geographical Breakdown of Product Revenue
| Region | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change ($) |
|---|---|---|---|
| North America | $31,514 | $25,983 | $5,531 |
| Europe, Middle East and Africa | $13,807 | $13,614 | $193 |
| Other | $696 | $175 | $521 |
| Total Product Revenue | $46,017 | $39,772 | $6,245 |
This geographical revenue breakdown indicates that North America remains the dominant market, contributing approximately 68% of total product revenue in Q3 2024.
A Deep Dive into Cerus Corporation (CERS) Profitability
A Deep Dive into Cerus Corporation's Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit on product revenue was $26,199 thousand, compared to $21,816 thousand for the same period in 2023. The gross margin on product sales was 57% in 2024, up from 55% in 2023. For the nine months ended September 30, 2024, gross profit was $72,137 thousand versus $60,441 thousand in 2023, maintaining a gross margin of 56% compared to 55% in the prior year.
Operating Profit Margin: The loss from operations for the three months ended September 30, 2024, was $(961) thousand, whereas it was $(5,243) thousand in the same period of 2023. The operating loss for the nine months ended September 30, 2024, was $(12,776) thousand compared to $(31,029) thousand in 2023.
Net Profit Margin: The net loss attributable to the company for the three months ended September 30, 2024, was $(2,934) thousand, improving from $(7,286) thousand in 2023. For the nine months, the net loss was $(18,399) thousand compared to $(36,258) thousand in the prior year.
| Metric | Q3 2024 | Q3 2023 | Change (%) | YTD 2024 | YTD 2023 | Change (%) |
|---|---|---|---|---|---|---|
| Gross Profit | $26,199 | $21,816 | 20% | $72,137 | $60,441 | 19.4% |
| Operating Loss | $(961) | $(5,243) | 81.7% | $(12,776) | $(31,029) | 58.8% |
| Net Loss | $(2,934) | $(7,286) | 59.8% | $(18,399) | $(36,258) | 49.3% |
Trends in Profitability Over Time: The company has shown improvement in profitability metrics over the past year. Gross profit has increased due to higher product revenue driven by sales volume growth. The reduction in operating loss highlights better cost management and operational efficiency, with total operating expenses decreasing from $34,538 thousand in Q3 2023 to $31,799 thousand in Q3 2024.
Comparison of Profitability Ratios with Industry Averages: As of September 2024, the gross margin of 57% is above the industry average of approximately 50% for biotechnology companies. The net profit margin also shows a positive trajectory, indicating a shift towards improved financial health compared to industry norms.
Analysis of Operational Efficiency: The reduction in operating loss and the increase in gross margin suggest effective cost management strategies. Research and development expenses decreased from $16,783 thousand in Q3 2023 to $14,013 thousand in Q3 2024, while selling, general, and administrative expenses remained stable, indicating a focus on optimizing operational costs.
Debt vs. Equity: How Cerus Corporation (CERS) Finances Its Growth
Debt vs. Equity: How Cerus Corporation Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, Cerus Corporation reported the following debt levels (in thousands):
| Debt Type | Current Amount | Non-Current Amount | Total Debt |
|---|---|---|---|
| Debt – Current | $18,521 | - | $18,521 |
| Debt – Non-Current | - | $64,847 | $64,847 |
| Total Debt | $18,521 | $64,847 | $83,368 |
The total debt has increased from $79,796 thousand as of December 31, 2023, to $83,368 thousand as of September 30, 2024.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Cerus Corporation as of September 30, 2024, is calculated as follows:
Debt-to-Equity Ratio = Total Debt / Total Equity
Total Equity as of September 30, 2024, was reported at $53,489 thousand.
Thus, the debt-to-equity ratio is:
Debt-to-Equity Ratio = $83,368 / $53,489 = 1.56
This ratio indicates a higher leverage compared to the industry average, which typically ranges from 0.5 to 1.0 for biotech companies.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
On March 31, 2023, Cerus Corporation entered into an Amended and Restated Credit, Security and Guaranty Agreement, securing a term loan facility totaling up to $75 million. This includes multiple tranches, with $40 million drawn initially. The interest rate is approximately 12.1%.
How the Company Balances Between Debt Financing and Equity Funding
In recent years, Cerus has primarily relied on public issuance of common stock and debt instruments to finance its operations. In the nine months ended September 30, 2024, the company reported net cash provided by financing activities of $4,218 thousand. This reflects a decrease from $9,490 thousand during the same period in 2023, largely due to repayments related to the revolving loan.
The balance between debt and equity financing is crucial for maintaining liquidity while supporting growth initiatives. The company has also seen an increase in cash and cash equivalents to $21,575 thousand as of September 30, 2024, up from $11,647 thousand at the end of 2023.
Overall, Cerus Corporation's approach involves leveraging debt to finance growth while maintaining a strategic balance with equity funding to support its operational and financial health.
Assessing Cerus Corporation (CERS) Liquidity
Assessing Cerus Corporation's Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
Current Assets: $140,612,000
Current Liabilities: $54,345,000
Current Ratio: 140,612 / 54,345 = 2.58
Quick Ratio: The quick ratio is calculated without inventories:
Quick Assets: $140,612,000 - $36,538,000 = $104,074,000
Quick Ratio: 104,074 / 54,345 = 1.92
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is:
Working Capital: $87,008,000 (compared to $78,392,000 as of December 31, 2023)
This indicates a positive trend in working capital, primarily due to increased product sales and improved cash collections.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow trends are as follows:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | $6,430 | $(27,985) |
| Net Cash (Used in) Provided by Investing Activities | $(844) | $408 |
| Net Cash Provided by Financing Activities | $4,218 | $9,490 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the total cash and cash equivalents, short-term investments, and restricted cash amount to:
Total Cash and Cash Equivalents: $77,199,000 (compared to $67,564,000 as of December 31, 2023)
Current debt stands at:
| Debt Type | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) |
|---|---|---|
| Current Debt | $18,521 | $20,000 |
| Non-current Debt | $64,847 | $59,796 |
| Total Debt | $83,368 | $79,796 |
Overall, the company demonstrates a strong liquidity position with a significant increase in cash reserves and a current ratio above 2.0, indicating good short-term financial health.
Is Cerus Corporation (CERS) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company is crucial for understanding whether it is overvalued or undervalued in the market. This section examines key financial ratios, stock price trends, dividend yield, and analyst consensus to provide a comprehensive view of the company's valuation.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company's P/E ratio stands at not applicable due to the negative earnings reported. The net loss attributable to the company for the third quarter of 2024 was $(2,934,000), leading to a basic net loss per share of $(0.02).
Price-to-Book (P/B) Ratio
The company's book value as of September 30, 2024, is $185,626,000, with total shares outstanding of 185,201,000. This results in a P/B ratio of approximately 1.00.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of the latest financial statements, the EBITDA for the nine months ended September 30, 2024, is reported at $(12,776,000), which is negative. Therefore, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
The stock price has fluctuated over the past 12 months. It opened the year at approximately $4.50 and has seen a range between $2.50 and $5.00.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0%. The payout ratio is also not applicable due to the absence of earnings.
Analyst Consensus on Stock Valuation
As of the latest reports, analysts have a consensus rating of Hold on the stock. This indicates a cautious outlook amid ongoing financial challenges.
| Valuation Metric | Value | Notes |
|---|---|---|
| P/E Ratio | Not Applicable | Negative earnings |
| P/B Ratio | 1.00 | Book value: $185,626,000 |
| EV/EBITDA Ratio | Not Applicable | Negative EBITDA |
| Stock Price (12-month range) | $2.50 - $5.00 | Opened year at $4.50 |
| Dividend Yield | 0% | No dividends paid |
| Analyst Consensus | Hold | Cautious outlook |
Key Risks Facing Cerus Corporation (CERS)
Key Risks Facing Cerus Corporation
The financial health of Cerus Corporation is influenced by various internal and external risk factors that investors should consider. These include industry competition, regulatory changes, and market conditions.
Industry Competition
The company operates in the highly competitive medical technology sector, particularly within the blood safety and pathogen reduction market. The presence of established players and new entrants increases the competition for market share, potentially impacting revenue growth. In the nine months ended September 30, 2024, the company reported a product revenue of $129.5 million, up from $109.6 million in the same period of the previous year, indicating a growth of 18%.
Regulatory Changes
Compliance with evolving regulatory requirements is critical for the company. The U.S. Food and Drug Administration (FDA) and European regulatory bodies continuously update their guidelines, which can affect product development timelines and costs. The company has incurred substantial expenses related to regulatory compliance, with research and development costs amounting to $43.5 million for the nine months ended September 30, 2024.
Market Conditions
Market volatility and macroeconomic factors can significantly affect the company’s operations. For instance, inflationary pressures may increase costs for materials and shipping. The company reported a decrease in government contract revenue, totaling $15.1 million for the nine months ended September 30, 2024, down from $23.9 million in the previous year, which reflects a decline of 37%.
Operational Risks
Operational challenges, including supply chain disruptions and manufacturing issues, pose risks to the company’s ability to meet demand. As of September 30, 2024, total liabilities stood at $135.3 million, which includes both current and non-current debts. The company reported current debt of $18.5 million and non-current debt of $64.8 million.
Financial Risks
Financial instability is evidenced by the company's net loss of $18.4 million for the nine months ended September 30, 2024, compared to a net loss of $36.3 million for the same period in 2023. The ability to secure additional funding is crucial, as the company continues to rely on public and private equity markets. The current cash and cash equivalents amount to $21.6 million.
Mitigation Strategies
To address these risks, the company is actively seeking to enhance its product offerings and streamline operations. As of September 30, 2024, working capital increased to $87.0 million from $78.4 million at the end of 2023. This improvement is attributed to increased product sales and effective cash collection strategies, which aid in sustaining operations amidst financial challenges.
| Risk Factor | Current Status | Mitigation Strategy |
|---|---|---|
| Industry Competition | Product revenue: $129.5 million (2024) | Enhancing product offerings |
| Regulatory Changes | R&D costs: $43.5 million (2024) | Ongoing compliance efforts |
| Market Conditions | Government contract revenue: $15.1 million (2024) | Diversification of revenue streams |
| Operational Risks | Total liabilities: $135.3 million | Supply chain management |
| Financial Risks | Net loss: $18.4 million (2024) | Securing additional funding |
Future Growth Prospects for Cerus Corporation (CERS)
Future Growth Prospects for Cerus Corporation
Analysis of Key Growth Drivers
The company has identified several key growth drivers that may enhance its future performance:
- Product Innovations: The ongoing development and enhancement of the INTERCEPT Blood System is expected to drive future revenue. The system has seen increased market acceptance, particularly in the U.S. and Europe.
- Market Expansions: The company is expanding its market presence in regions where commercialization efforts are underway, which is anticipated to contribute to revenue growth.
- Acquisitions: Strategic acquisitions may further bolster growth by enhancing product offerings and market access.
Future Revenue Growth Projections and Earnings Estimates
Revenue growth projections for the company indicate a strong upward trend. For the nine months ended September 30, 2024, product revenue reached $129,461 thousand, up from $109,599 thousand in 2023, reflecting an increase of 18% year-over-year.
Additionally, the total revenue for the same period was $144,570 thousand, compared to $133,455 thousand in 2023, marking an 8% increase.
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has entered multiple agreements aimed at enhancing its product development capabilities:
- In September 2020, a five-year agreement with the FDA was established for the development of next-generation compounds, valued at $11.1 million.
- A partnership with the DoD for the development of pathogen-reduced, lyophilized cryoprecipitate was amended in May 2023, increasing its total contract value from $9.1 million to $17.8 million.
Competitive Advantages That Position the Company for Growth
The company benefits from several competitive advantages:
- Established Market Position: The INTERCEPT Blood System is recognized as a leading product in blood safety, which enhances customer trust and market penetration.
- Strong Customer Relationships: Significant customers such as the American Red Cross account for 35% of product revenue, ensuring stable demand.
- Robust R&D Pipeline: Continuous investment in research and development ensures a steady stream of innovative products, maintaining competitive edge in the market.
| Financial Metrics | 2024 (9 Months) | 2023 (9 Months) | Change (%) |
|---|---|---|---|
| Product Revenue | $129,461 thousand | $109,599 thousand | 18% |
| Total Revenue | $144,570 thousand | $133,455 thousand | 8% |
| Government Contract Revenue | $15,109 thousand | $23,856 thousand | -37% |
| Gross Profit on Product Revenue | $72,137 thousand | $60,441 thousand | 19% |
Cerus Corporation (CERS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Cerus Corporation (CERS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Cerus Corporation (CERS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Cerus Corporation (CERS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.